Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6‐mercaptopurine and azathioprine.

CL Szumlanski, RM Weinshilboum

Research output: Contribution to journalArticlepeer-review

205 Scopus citations

Abstract

Thiopurine drugs are used in the treatment of inflammatory bowel disease—as are sulphasalazine and its metabolite 5‐aminosalicylic acid (ASA). S‐Methylation catalyzed by thiopurine methyltransferase (TPMT) is a major pathway in the metabolism of thiopurines. The hypothesis was tested that TPMT might be inhibited by sulphasalazine or isomers of ASA. Sulphasalazine as well as 3‐, 4‐ and 5‐ASA inhibited recombinant human TPMT, with IC50 values of 78, 99, 2600 and 1240 microM, respectively. Kinetic studies demonstrated that the inhibition of TPMT by sulphasalazine and ASA isomers was non‐competitive with regard to the thiopurine substrate, 6‐MP, and was uncompetitive with regard to the methyl donor for the reaction, S‐adenosyl‐L‐methionine. Our observations raise the possibility of a clinically significant drug‐ drug interaction in patients treated simultaneously with sulphasalazine and thiopurine drugs. 1995 The British Pharmacological Society

Original languageEnglish (US)
Pages (from-to)456-459
Number of pages4
JournalBritish Journal of Clinical Pharmacology
Volume39
Issue number4
DOIs
StatePublished - Apr 1995

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6‐mercaptopurine and azathioprine.'. Together they form a unique fingerprint.

Cite this